General Information of Drug Transporter (DT)
DT ID	DTD0016 Transporter Info
Gene Name	ABCC5
Protein Name	Multidrug resistance-associated protein 5
Gene ID	10057
UniProt ID	O15440
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs10937158
Site of GPD	chr3:183990651 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.3171/1588 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the decreased diarrhea risk in patients (compare with genotype CC)		[ 1]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the decreased diarrhea risk in patients (compare with genotype CC)		[ 1]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the decreased diarrhea risk in patients (compare with genotype CC)		[ 1]
Fluorouracil	N.A.	Diarrhea	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Irinotecan	N.A.	Diarrhea	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Leucovorin	N.A.	Diarrhea	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Fluorouracil	N.A.	Colorectal Neoplasms	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Allele T is associated with decreased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype CC.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CC genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the CT + TT genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the CT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the TT genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genetic Polymorphism	rs3749438
Site of GPD	chr3:183987396 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.3339/1672 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased diarrhea risk in patients (compare with genotype GG)		[ 1]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased diarrhea risk in patients (compare with genotype GG)		[ 1]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased diarrhea risk in patients (compare with genotype GG)		[ 1]
Fluorouracil	N.A.	Diarrhea	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Irinotecan	N.A.	Diarrhea	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Leucovorin	N.A.	Diarrhea	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Fluorouracil	N.A.	Colorectal Neoplasms	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Allele A is associated with increased risk of Diarrhea when treated with fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotype GG.		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the AA genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the AG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have an increased risk for grade 3–4 severe diarrhea as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Fluorouracil	N.A.	Colorectal Neoplasms	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Leucovorin	N.A.	Colorectal Neoplasms	Patients with the GG genotype and Colorectal Neoplasms who are treated with fluorouracil, irinotecan and leucovorin may have a decreased, but not absent, risk for grade 3–4 severe diarrhea as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's risk for grade 3–4 severe diarrhea.		[ 1]
Genetic Polymorphism	rs939338
Site of GPD	chr3:183986280 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.3010/595 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cisplatin	N.A.	Progression-free Survival	Allele G is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele A.		[ 2]
Doxorubicin	N.A.	Progression-free Survival	Allele G is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele A.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Genetic Polymorphism	rs562
Site of GPD	chr3:183920057 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.4580/906 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Drug Toxicity	Genotype CC is associated with increased likelihood of Drug Toxicity when treated with irinotecan in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 4]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 5]
Genetic Polymorphism	rs1533682
Site of GPD	chr3:183917091 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.3000/593 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Doxorubicin	N.A.	Drug Toxicity	Genotype TT is associated with increased clearance of doxorubicin in women with Breast Neoplasms as compared to genotypes CC + CT.		[ 6]
Genetic Polymorphism	rs3749442
Site of GPD	chr3:183942797 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.7550/1494 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Glyburide	N.A.	Drug Toxicity	Allele A is associated with increased response to glibenclamide in people with as compared to allele G.		[ 7]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype AA is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 3]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cannabidiol	N.A.	Anemia	Genotypes AA + AG are associated with decreased response to cannabidiol in people with Epilepsy as compared to genotype GG.		[ 8]
Cannabidiol	N.A.	Sedation	Genotypes AA + AG are associated with increased likelihood of sedation when treated with cannabidiol in people with Epilepsy as compared to genotype GG.		[ 8]
Genetic Polymorphism	rs4148579
Site of GPD	chr3:183967461 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.3000/593 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 3]
Genetic Polymorphism	rs4148580
Site of GPD	chr3:183967395 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	T=0.8500/1682 (Global)
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype CC is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 3]
Genetic Polymorphism	rs4148575
Site of GPD	chr3:183984487 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.3210/635 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Genetic Polymorphism	rs1132776
Site of GPD	chr3:183978614 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.3240/641 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Antineoplastic And Immunomodulating Agents	N.A.	Neutropenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Leukopenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Thrombocytopenia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Antineoplastic And Immunomodulating Agents	N.A.	Anemia	Genotype GG is associated with increased severity of Neutropenia, Leukopenia, Thrombocytopenia or Anemia when treated with Antineoplastic And Immunomodulating Agents in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG.		[ 3]
Genetic Polymorphism	rs2293001
Site of GPD	chr3:183982423 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G / C>T
Minor Allele Frequency	C=0.5710/1130 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele C.		[ 5]
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele C is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele T.		[ 9]
Genetic Polymorphism	rs9838667
Site of GPD	chr3:183946890 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.6570/1300 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Drugs For Treatment Of Tuberculosis	N.A.	Toxic Liver Disease	Allele T is not associated with risk of Toxic liver disease due to Drugs For Treatment Of Tuberculosis in people with Tuberculosis as compared to allele G.		[ 5]
Genetic Polymorphism	rs4148557
Site of GPD	chr3:184015996 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.3440/680 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 9]
Genetic Polymorphism	rs4148572
Site of GPD	chr3:184002711 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A / C>G
Minor Allele Frequency	C=0.8490/1680 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 9]
Genetic Polymorphism	rs3792581
Site of GPD	chr3:183978082 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>A
Minor Allele Frequency	C=0.7530/1490 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 9]
Genetic Polymorphism	rs3805111
Site of GPD	chr3:183972201 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.9400/1860 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 9]
Genetic Polymorphism	rs2139560
Site of GPD	chr3:183936081 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.3020/597 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele A is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele G.		[ 9]
Genetic Polymorphism	rs8180093
Site of GPD	chr3:183924515 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.9210/1822 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele G is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele A.		[ 9]
Genetic Polymorphism	rs1000002
Site of GPD	chr3:183917980 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.6250/1236 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Antiepileptics	N.A.	Toxic Liver Disease	Allele T is not associated with resistance to antiepileptics in people with Epilepsy as compared to allele C.		[ 9]
References
1	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenet Genomics. 2015 Dec;25(12):573-83.
2	A First Step toward Personalized Medicine in Osteosarcoma: Pharmacogenetics as Predictive Marker of Outcome after Chemotherapy-Based Treatment. Clin Cancer Res. 2015 Aug 01;21(15):3436-41.
3	Association between genetic variants of membrane transporters and the risk of high-grade hematologic adverse events in a cohort of Mexican children with B-cell acute lymphoblastic leukemia. Front Oncol. 2023;13:1276352.
4	Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study. Cancer Biol Ther. 2011 Nov 01;12(9):780-7.
5	Association of ABCC Gene Polymorphism With Susceptibility to Antituberculosis Drug-Induced Hepatotoxicity in Western Han Patients With Tuberculosis. J Clin Pharmacol. 2020 Mar;60(3):361-368.
6	Pharmacogenetics of ABCB5, ABCC5 and RLIP76 and doxorubicin pharmacokinetics in Asian breast cancer patients. Pharmacogenomics J. 2017 Jul;17(4):337-343.
7	Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes. Diabetes Technol Ther. 2016 Sep;18(9):586-93.
8	Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy. Clin Pharmacol Ther. 2021 Nov;110(5):1368-1380.
9	Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy. Pharmacogenomics. 2011 Mar;12(3):319-25.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.